Anabolic steroids, technically known as anabolic-androgenic steroids (AAS), are drugs that are structurally related to the cyclic steroid ring system and have similar effects to testosterone in the body. They increase protein within cells, especially in skeletal muscles. Anabolic steroids also have androgenic and virilizing properties, including the development and maintenance of masculine characteristics such as the growth of the vocal cords, testicles (primary sexual characteristics) and body hair (secondary sexual characteristics). The word anabolic comes from the Greek ἀναβολή anabole, "that which is thrown up, mound", and the word androgenic from the Greek ἀνδρός andros, "of a man" + -γενής -genes, "born".
Anabolic steroids were first made in the 1930s, and are now used therapeutically in medicine to stimulate muscle growth and appetite, induce male puberty and treat chronic wasting conditions, such as cancer and AIDS. The American College of Sports Medicine acknowledges that AAS, in the presence of adequate diet, can contribute to increases in body weight, often as lean mass increases and that the gains in muscular strength achieved through high-intensity exercise and proper diet can be additionally increased by the use of AAS in some individuals.
Health risks can be produced by long-term use or excessive doses of anabolic steroids. These effects include harmful changes in cholesterol levels (increased low-density lipoprotein and decreased high-density lipoprotein), acne, high blood pressure, liver damage (mainly with oral steroids), and dangerous changes in the structure of the left ventricle of the heart. Conditions pertaining to hormonal imbalances such as gynecomastia and testicular atrophy may also be caused by anabolic steroids.
Ergogenic uses for anabolic steroids in sports, racing, and bodybuilding as performance-enhancing drugs are controversial because of their adverse effects and the potential to gain unfair advantage is considered cheating. Their use is referred to as doping and banned by all major sporting bodies. For many years, AAS have been by far the most detected doping substances in IOC-accredited laboratories. In countries where AAS are controlled substances, there is often a black market in which smuggled, clandestinely manufactured or even counterfeit drugs are sold to users.
- 1 List of anabolic steroids
- 2 Pharmacology
- 3 Medical and ergogenic uses
- 4 Adverse effects
- 4.1 Neuropsychiatric
- 4.2 Physiological
- 5 AAS abuse
- 5.1 Abuse potential
- 5.2 Causes and treatment
- 5.3 Illicit use by groups
- 5.4 Tragedies involving AAS abuse
- 6 Legal and sport restrictions
- 7 Illegal trade
- 8 History
- 9 See also
- 10 References
- 11 Further reading
- 12 External links
List of anabolic steroids
Exogenous anabolic androgenic steroids
Endogenous anabolic androgenic steroids
- Prasterone (dehydroepiandrosterone DHEA)
Metabolites and isomers
Metabolites and isomers of endogenous anabolic androgenic steroids, including, but not limited to:
Routes of administrations
There are four common forms in which anabolic steroids are administered: oral pills; injectable steroids; creams/gels for topical application; and skin patches. Oral administration is the most convenient. Testosterone administered by mouth is rapidly absorbed, but it is largely converted to inactive metabolites, and only about 1/6 is available in active form. In order to be sufficiently active when given by mouth, testosterone derivatives are alkylated at the 17 position, e.g. methyltestosterone and fluoxymesterone. This modification reduces the liver's ability to break down these compounds before they reach the systemic circulation.
Testosterone can be administered parenterally, but it has more irregular prolonged absorption time and greater activity in muscleenanthate, undecanoate, or cypionate ester form. These derivatives are hydrolyzed to release free testosterone at the site of injection; absorption rate (and thus injection schedule) varies among different esters, but medical injections are normally done anywhere between semi-weekly to once every 12 weeks. A more frequent schedule may be desirable in order to maintain a more constant level of hormone in the system. Injectable steroids are typically administered into the muscle, not into the vein, to avoid sudden changes in the amount of the drug in the bloodstream. In addition, because estered testosterone is dissolved in oil, intravenous injection has the potential to cause a dangerous embolism (clot) in the bloodstream.
Transdermal patches (adhesive patches placed on the skin) may also be used to deliver a steady dose through the skin and into the bloodstream. Testosterone-containing creams and gels that are applied daily to the skin are also available, but absorption is inefficient (roughly 10%, varying between individuals) and these treatments tend to be more expensive. Individuals who are especially physically active and/or bathe often may not be good candidates, since the medication can be washed off and may take up to six hours to be fully absorbed. There is also the risk that an intimate partner or child may come in contact with the application site and inadvertently dose himself or herself; children and women are highly sensitive to testosterone and can suffer unintended masculinization and health effects, even from small doses. Injection is the most common method used by individuals administering anabolic steroids for non-medical purposes.
The traditional routes of administration do not have differential effects on the efficacy of the drug. Studies indicate that the anabolic properties of anabolic steroids are relatively similar despite the differences in pharmacokinetic principles such as first-pass metabolism. However, the orally available forms of AAS may cause liver damage in high doses.
Mechanism of action
The pharmacodynamics of anabolic steroids are unlike peptide hormones. Water-soluble peptide hormones cannot penetrate the fatty cell membrane and only indirectly affect the nucleus of target cells through their interaction with the cell’s surface receptors. However, as fat-soluble hormones, anabolic steroids are membrane-permeable and influence the nucleus of cells by direct action. The pharmacodynamic action of anabolic steroids begin when the exogenous hormone penetrates the membrane of the target cell and binds to an androgen receptor located in the cytoplasm of that cell. From there, the compound hormone-receptor diffuses into the nucleus, where it either alters the expression of genes or activates processes that send signals to other parts of the cell. Different types of anabolic steroids bind to the androgen receptor with different affinities, depending on their chemical structure. Some anabolic steroids such as methandrostenolone bind weakly to this receptor in vitro, but still exhibit androgenic effects in vivo. The reason for this discrepancy is not known.
The effect of anabolic steroids on muscle mass is caused in at least two ways: first, they increase the production of proteins; second, they reduce recovery time by blocking the effects of stress hormone cortisol on muscle tissue, so that catabolism of muscle is greatly reduced. It has been hypothesized that this reduction in muscle breakdown may occur through anabolic steroids inhibiting the action of other steroid hormones called glucocorticoids that promote the breakdown of muscles. Anabolic steroids also affect the number of cells that develop into fat-storage cells, by favouring cellular differentiation into muscle cells instead. Anabolic steroids can also decrease fat by increasing basal metabolic rate (BMR), since an increase in muscle mass increases BMR.
Anabolic and androgenic effects
As the name suggests, anabolic-androgenic steroids have two different, but overlapping, types of effects: anabolic, meaning that they promote anabolism (cell growth), and androgenic (or virilising), meaning that they affect the development and maintenance of masculine characteristics.
Some examples of the anabolic effects of these hormones are increased protein synthesis from amino acids, increased appetite, increased bone remodeling and growth, and stimulation of bone marrow, which increases the production of red blood cells. Through a number of mechanisms anabolic steroids stimulate the formation of muscle cells and hence cause an increase in the size of skeletal muscles, leading to increased strength.
The androgenic effects of AAS are numerous. Depending on the length of use, the side effects of the steroid can be irreversible. Processes affected include pubertal growth, sebaceous gland oil production, and sexuality (especially in fetal development). Some examples of virilizing effects are growth of the clitoris in females and the penis in male children (the adult penis size does not change due to steroids[medical citation needed] ), increased vocal cord size, increased libido, suppression of natural sex hormones, and impaired production of sperm. Effects on women include deepening of the voice, facial hair growth, and possibly a decrease in breast size. Men may develop an enlargement of breast tissue, known as gynecomastia, testicular atrophy, and a reduced sperm count.
The androgenic:anabolic ratio of an AAS is an important factor when determining the clinical application of these compounds. Compounds with a high ratio of androgenic to an anabolic effects are the drug of choice in androgen-replacement therapy (e.g., treating hypogonadism in males), whereas compounds with a reduced androgenic:anabolic ratio are preferred for anemia and osteoporosis, and to reverse protein loss following trauma, surgery, or prolonged immobilization. Determination of androgenic:anabolic ratio is typically performed in animal studies, which has led to the marketing of some compounds claimed to have anabolic activity with weak androgenic effects. This disassociation is less marked in humans, where all anabolic steroids have significant androgenic effects.
A commonly used protocol for determining the androgenic:anabolic ratio, dating back to the 1950s, uses the relative weights of ventral prostate (VP) and levator ani muscle (LA) of male rats. The VP weight is an indicator of the androgenic effect, while the LA weight is an indicator of the anabolic effect. Two or more batches of rats are castrated and given no treatment and respectively some AAS of interest. The LA/VP ratio for an AAS is calculated as the ratio of LA/VP weight gains produced by the treatment with that compound using castrated but untreated rats as baseline: (LAc,t–LAc)/(VPc,t–VPc). The LA/VP weight gain ratio from rat experiments is not unitary for testosterone (typically 0.3–0.4), but it is normalized for presentation purposes, and used as basis of comparison for other AAS, which have their androgenic:anabolic ratios scaled accordingly (as shown in the table above). In the early 2000s, this procedure was standardized and generalized throughout OECD in what is now known as the Hershberger assay.
Body composition and strength improvements
A review spanning more than three decades of experimental studies in men found that body weight may increase by 2–5 kg as a result of short-term (<10 weeks) AAS use, which may be attributed mainly to an increase of lean mass. Animal studies also found that fat mass was reduced, but most studies in humans failed to elucidate significant fat mass decrements. The effects on lean body mass have been shown to be dose-dependent. Both muscle hypertrophy and the formation of new muscle fibers have been observed. The hydration of lean mass remains unaffected by AAS use, although small increments of blood volume cannot be ruled out.
The upper region of the body (thorax, neck, shoulders, and upper arm) seems to be more susceptible for AAS than other body regions because of predominance of androgen receptors in the upper body. The largest difference in muscle fiber size between AAS users and non-users was observed in type I muscle fibers of the vastus lateralis and the trapezius muscle as a result of long-term AAS self-administration. After drug withdrawal, the effects fade away slowly, but may persist for more than 6–12 weeks after cessation of AAS use.
The same review observed strength improvements in the range of 5–20% of baseline strength, depending largely on the drugs and dose used as well as the administration period. Overall, the exercise where the most significant improvements were observed is the bench press. For almost two decades, it was assumed that AAS exerted significant effects only in experienced strength athletes, particularly based on the studies of Hervey and coworkers. In 1996, a randomized controlled trial published in the New England Journal of Medicine demonstrated, however, that even in novice athletes a 10-week strength training program accompanied by testosterone enanthate at 600 mg/week may improve strength more than training alone does. The same study found that dose to be sufficient to significantly improve lean muscle mass relative to placebo even in subjects that did not exercise at all. A 2001 study by the same first author, showed that the anabolic effects of testosterone enanthate were highly dose dependent.
Medical and ergogenic uses
Since the discovery and synthesis of testosterone in the 1930s, anabolic steroids have been used by physicians for many purposes, with varying degrees of success, for the treatment of:
- Bone marrow stimulation: For decades, anabolic steroids were the mainstay of therapy for hypoplastic anemias due to leukemia or kidney failure, especially aplastic anemia. Anabolic steroids have largely been replaced in this setting by synthetic protein hormones (such as epoetin alfa) that selectively stimulate growth of blood cell precursors.
- Growth stimulation: Anabolic steroids can be used by pediatric endocrinologists to treat children with growth failure. However, the availability of synthetic growth hormone, which has fewer side effects, makes this a secondary treatment.
- Stimulation of appetite and preservation and increase of muscle mass: Anabolic steroids have been given to people with chronic wasting conditions such as cancer and AIDS.
- Induction of male puberty: Androgens are given to many boys distressed about extreme delay of puberty. Testosterone is now nearly the only androgen used for this purpose and has been shown to increase height, weight, and fat-free mass in boys with delayed puberty.
- Male contraception, in the form of testosterone enanthate; potential for use in the near-future as a safe, reliable, and reversible male contraceptive.
- Stimulation of lean body mass and prevention of bone loss in elderly men, as some studies indicate. However, a 2006 placebo-controlled trial of low-dose testosterone supplementation in elderly men with low levels of testosterone found no benefit on body composition, physical performance, insulin sensitivity, or quality of life.
- Hormone replacement for men with low levels of testosterone; also effective in improving libido for elderly males.
- Gender Identity Disorder, by producing secondary male characteristics, such as a deeper voice, increased bone and muscle mass, facial hair, increased levels of red blood cells, and clitoral enlargement in female-to-male patients.
Ergogenic use and abuse
Most steroid users are not athletes. Between 1 million and 3 million people (1% of the population) are thought to have misused AAS in the United States. Studies in the United States have shown that anabolic steroid users tend to be mostly middle-class heterosexual men with a median age of about 25 who are noncompetitive bodybuilders and non-athletes and use the drugs for cosmetic purposes. "Among 12- to 17-year-old boys, use of steroids and similar drugs jumped 25 percent from 1999 to 2000, with 20 percent saying they use them for looks rather than sports, a study by insurer Blue Cross Blue Shield found."(Eisenhauer) Another study found that non-medical use of AAS among college students was at or less than 1%. According to a recent survey, 78.4% of steroid users were noncompetitive bodybuilders and non-athletes, while about 13% reported unsafe injection practices such as reusing needles, sharing needles, and sharing multidose vials, though a 2007 study found that sharing of needles was extremely uncommon among individuals using anabolic steroids for non-medical purposes, less than 1%. Another 2007 study found that 74% of non-medical anabolic steroid users had secondary college degrees and more had completed college and fewer had failed to complete high school than is expected from the general populace. The same study found that individuals using anabolic steroids for non-medical purposes had a higher employment rate and a higher household income than the general population. Anabolic steroid users tend to research the drugs they are taking more than other controlled-substance users; however, the major sources consulted by steroid users include friends, non-medical handbooks, internet-based forums, blogs, and fitness magazines, which can provide questionable or inaccurate information.
Anabolic steroid users tend to be disillusioned by the portrayal of anabolic steroids as deadly in the media and in politics. According to one study, AAS users also distrust their physicians and in the sample 56% had not disclosed their AAS use to their physicians. Another 2007 study had similar findings, showing that, while 66% of individuals using anabolic steroids for non-medical purposes were willing to seek medical supervision for their steroid use, 58% lacked trust in their physicians, 92% felt that the medical community's knowledge of non-medical anabolic steroid use was lacking, and 99% felt that the public has an exaggerated view of the side-effects of anabolic steroid use. A recent study has also shown that long term AAS users were more likely to have symptoms of muscle dysmorphia and also showed stronger endorsement of more conventional male roles.
Anabolic steroids have been used by men and women in many different kinds of professional sports to attain a competitive edge or to assist in recovery from injury. These sports include bodybuilding, weightlifting, shot put and other track and field, cycling, baseball, wrestling, mixed martial arts, boxing, football, and cricket. Such use is prohibited by the rules of the governing bodies of most sports. Anabolic steroid use occurs among adolescents, especially by those participating in competitive sports. It has been suggested that the prevalence of use among high-school students in the U.S. may be as high as 2.7%. Male students used anabolic steroids more frequently than female students and, on average, those that participated in sports used steroids more often than those that did not.
Anabolic steroid can cause many adverse effects.
A 2005 review in CNS Drugs determined that "significant psychiatric symptoms including aggression and violence, mania, and less frequently psychosis and suicide have been associated with steroid abuse. Long-term steroid abusers may develop symptoms of dependence and withdrawal on discontinuation of AAS". High concentrations of AAS, comparable to those likely sustained by many recreational AAS users, produce apoptotic effects on neurons, raising the specter of possibly irreversible neuropsychiatric toxicity. Recreational AAS use appears to be associated with a range of potentially prolonged psychiatric effects, including dependence syndromes, mood disorders, and progression to other forms of substance abuse, but the prevalence and severity of these various effects remains poorly understood. There is no evidence that steroid dependence develops from therapeutic use of anabolic steroids to treat medical disorders, but instances of AAS dependence have been reported among weightlifters and bodybuilders who chronically administered supraphysiologic doses. Mood disturbances (e.g. depression, [hypo-]mania, psychotic features) are likely to be dose- and drug-dependent, but AAS dependence or withdrawal effects seem to occur only in a small number of AAS users.
Large-scale long-term studies of psychiatric effects on AAS users are not currently available. In 2003, the first naturalistic long-term study on ten users, seven of which having completed the study, found a high incidence of mood disorders and substance abuse, but few clinically relevant changes in physiological parameters or laboratory measures were noted throughout the study, and these changes were not clearly related to periods of reported AAS use. A 13-month study, which was published in 2006 and which involved 320 body builders and athletes suggests that the wide range of psychiatric side-effects induced by the use of AAS is correlated to the severity of abuse.
DSM-IV lists General diagnostic criteria for a personality disorder guideline that "The pattern must not be better accounted for as a manifestation of another mental disorder, or to the direct physiological effects of a substance (e.g. drug or medication) or a general medical condition (e.g. head trauma).". As a result anabolic steroid users may get misdiagnosed by psychiatrist not told about their habit.
Cooper, Noakes, Dunne, Lambert, and Rochford identified that anabolic–androgenic steroid (AAS) using individuals are more likely to score higher on borderline (4.7 times), antisocial (3.8 times), paranoid (3.4 times), schizotypal (3.1 times), histrionic (2.9 times), passive-aggressive (2.4 times), and narcissistic (1.6 times) personality profiles than non-users. Other studies have suggested that antisocial personality disorder is slightly more likely among anabolic steroid users than among non-users (Pope & Katz, 1994). Bipolar dysfunction, substance dependency, and conduct disorder have also been associated with AAS use.
Mood and anxiety
Affective disorders have long been recognised as a complication of anabolic steroid use. Case reports describe both hypomania and mania, along with irritability, elation, recklessness, racing thoughts and feelings of power and invincibility that did not meet the criteria for mania/hypomania. Of 53 bodybuilders who used anabolic steroids, 27 (51%) reported unspecified mood disturbance.
Aggression and hypomania
From the mid-1980s onward, the media reported "roid rage" as a side-effect of AAS.
A 2005 review determined that some, but not all, randomized controlled studies have found that anabolic steroid use correlates with hypomania and increased aggressiveness, but pointed out that attempts to determine whether AAS use triggers violent behavior have failed, primarily because of high rates of non-participation. A 2008 study on a nationally representative sample of young adult males in the United States found an association between lifetime and past-year self-reported anabolic-androgenic steroid use and involvement in violent acts. Compared with individuals that did not use steroids, young adult males that used anabolic-androgenic steroids reported greater involvement in violent behaviors even after controlling for the effects of key demographic variables, previous violent behavior, and polydrug use. A 1996 review examining the blind studies available at that time also found that these had demonstrated a link between aggression and steroid use, but pointed out that with estimates of over one million past or current steroid users in the United States at that time, an extremely small percentage of those using steroids appear to have experienced mental disturbance severe enough to result in clinical treatments or medical case reports.
A 1996 randomized controlled trial, which involved 43 men, did not find an increase in the occurrence of angry behavior during 10 weeks of administration of testosterone enanthate at 600 mg/week, but this study screened out subjects that had previously abused steroids or had any psychiatric antecedents. A trial conducted in 2000 using testosterone cypionate at 600 mg/week found that treatment significantly increased manic scores on the YMRS, and aggressive responses on several scales. The drug response was highly variable. However: 84% of subjects exhibited minimal psychiatric effects, 12% became mildly hypomanic, and 4% (2 subjects) became markedly hypomanic. The mechanism of these variable reactions could not be explained by demographic, psychological, laboratory, or physiological measures.
A 2006 study of two pairs of identical twins, in which one twin used anabolic steroids and the other did not, found that in both cases the steroid-using twin exhibited high levels of aggressiveness, hostility, anxiety, and paranoid ideation not found in the "control" twin. A small-scale study of 10 AAS users found that cluster B personality disorders were confounding factors for aggression.
Depression and suicide
The relationship between AAS use and depression is inconclusive. There have been anecdotal reports of depression and suicide in teenage steroid users, but little systematic evidence. A 1992 review found that anabolic-androgenic steroids may both relieve and cause depression, and that cessation or diminished use of anabolic-androgenic steroids may also result in depression, but called for additional studies due to disparate data. In the case of suicide, 3.9% of a sample of 77 those classified as AAS users reported attempting suicide during withdrawal (Malone, Dimeff, Lombardo, & Sample, 1995).
Depending on the length of drug abuse, there is a chance that the immune system can be damaged. Most of these side-effects are dose-dependent, the most common being elevated blood pressure, especially in those with pre-existing hypertension,
Anabolic steroids have been shown to alter fasting blood sugar and glucose tolerance tests. Anabolic steroids such as testosterone also increase the risk of cardiovascular disease or coronary artery disease. Acne is fairly common among anabolic steroid users, mostly due to stimulation of the sebaceous glands by increased testosterone levels. Conversion of testosterone to dihydrotestosterone (DHT) can accelerate the rate of premature baldness for males genetically predisposed, but testosterone itself can produce baldness in females.
A number of severe side-effects can occur if adolescents use anabolic steroids.
For example, the steroids may prematurely stop the lengthening of bones (premature epiphyseal fusion through increased levels of estrogen metabolites), resulting in stunted growth. Other effects include, but are not limited to, accelerated bone maturation, increased frequency and duration of erections, and premature sexual development. Anabolic steroid use in adolescence is also correlated with poorer attitudes related to health.
Other side-effects can include alterations in the structure of the heart, such as enlargement and thickening of the left ventricle, which impairs its contraction and relaxation. Possible effects of these alterations in the heart are hypertension, cardiac arrhythmias, congestive heart failure, heart attacks, and sudden cardiac death. These changes are also seen in non-drug-using athletes, but steroid use may accelerate this process. However, both the connection between changes in the structure of the left ventricle and decreased cardiac function, as well as the connection to steroid use have been disputed.
AAS use can cause harmful changes in cholesterol levels: Some steroids cause an increase in LDL "bad" cholesterol and a decrease in HDL "good" cholesterol. In addition, steroids provoke a rapid increase in body weight and an accompanying rise in blood pressure, both of which leave users more vulnerable to a cardiovascular event.
An important side effect to mention for high school athletes because steroids can cause the premature closure of the growth plate, leading to stunted growth.
There are also sex-specific side effects of anabolic steroids. Development of breast tissue in males, a condition called gynecomastia (which is usually caused by high levels of circulating estradiol), may arise because of increased conversion of testosterone to estradiol by the enzyme aromatase. Reduced sexual function and temporary infertility can also occur in males. Another male-specific side-effect that can occur is testicular atrophy, caused by the suppression of natural testosterone levels, which inhibits production of sperm (most of the mass of the testes is developing sperm). This side-effect is temporary: The size of the testicles usually returns to normal within a few weeks of discontinuing anabolic steroid use as normal production of sperm resumes.
Female-specific side effects include increases in body hair, permanent deepening of the voice, enlarged clitoris, and temporary decreases in menstrual cycles. When taken during pregnancy, anabolic steroids can affect fetal development by causing the development of male features in the female fetus and female features in the male fetus.
Kidney tests revealed that nine of the ten bodybuilders developed a condition called focal segmental glomerulosclerosis, a type of scarring within the kidneys. The kidney damage in the bodybuilders has similarities to that seen in morbidly obese patients, but appears to be even more severe.
High doses of oral anabolic steroid compounds can cause liver damage, as the steroids are metabolized (17α-alkylated) in the digestive system to increase their bioavailability and stability. Peliosis hepatis has been increasingly recognised with the use of anabolic steroids.
Anabolic steroids are not psychoactive and cannot be detected by stimuli devices like a pupilometer which makes them hard to spot as a source of neuropsychological imbalaces in some AAS users.
Research data indicates that steroids affect the serotonin and dopamine neurotransmitter systems of the brain. In an animal study, male rats developed a conditioned place preference to testosterone injections into the nucleus accumbens, an effect blocked by dopamine antagonists, which suggests that androgen reinforcement is mediated by the brain. Moreover, testosterone appears to act through the mesolimbic dopamine system, a common substrate for drugs of abuse. Nonetheless, androgen reinforcement is not comparable to that of cocaine, nicotine, or heroin. Instead, testosterone resembles other mild reinforcers, such as caffeine, or benzodiazepines. The potential for androgen addiction remains to be determined. However, abuse of steroids is rivalling heroin use in Britain.
The Diagnostic Statistical Manual IV (DSM IV) and the International Classification of Diseases, Volume 10 (ICD 10) differ in the way they regard Anabolic-Androgenic Steroids' (AAS) potential for producing dependence. DSM IV regards AAS as potentially dependence producing. ICD 10 however regards them as non-dependence producing. Anabolic steroids are not physically addictive but users can develop a psychological dependence on the physical result.
For DSM-IV, anabolic-androgenic steroid dependency is found in the “other substance-related disorder” (include inhalants, anabolic steroids, medications) section and can be coded, depending on which diagnostic criteria are met.
ICD–10 criteria for dependence include experience of at least three of the following during the past year:
- a strong desire to take steroids
- difficulty in controlling use
- withdrawal syndrome when use is reduced
- evidence of tolerance
- neglect of other interests and persistent use despite harmful consequences
However, the following ICD-10-CM Index entries contain back-references to ICD-10-CM F55.3:
- hormones F55.5
- steroids F55.5
- drug NEC (non-dependent) F19.10
- hormones F55.5
- steroids F55.5
- non-psychoactive substance NEC F55.8
- hormones F55.5
- steroids F55.5
ICD-10 goes on to state that “although it is usually clear that the patient has a strong motivation to take the substance, there is no development of dependence or withdrawal symptoms as in the case of the psychoactive substances.”
ICD-9-CM will be replaced by ICD-10-CM beginning October 1, 2014, therefore, F55.3 and all other ICD-10-CM diagnosis codes should only be used for training or planning purposes until then.
National Institute on Drug Abuse
The National Institute on Drug Abuse (NIDA) says that "even though anabolic steroids do not cause the same high as other drugs, steroids are reinforcing and can lead to addiction. Studies have shown that animals will self-administer steroids when given the opportunity, just as they do with other addictive drugs. People may persist in abusing steroids despite physical problems and negative effects on social relationships, reflecting these drugs’ addictive potential. Also, steroid abusers typically spend large amounts of time and money obtaining the drug; another indication of addiction. Individuals who abuse steroids can experience withdrawal symptoms when they stop taking them, including mood swings, fatigue, restlessness, loss of appetite, insomnia, reduced sex drive, and steroid cravings, all of which may contribute to continued abuse. One of the most dangerous withdrawal symptoms is depression. When depression is persistent, it can sometimes lead to suicidal thoughts. Research has found that some steroid abusers turn to other drugs such as opioid to counteract the negative effects of steroids."
Causes and treatment
Male anabolic-androgenic steroid abusers often have a troubled social background.
25% of male weightlifters reported memories of childhood physical or sexual abuse in an interview. Anabolic steroids are sometimes used by people with muscle dysmorphia (a very specific type of body dysmorphic disorder (BDD)) as a defense mechanism. Interestingly, yohimbine, while it was originally considered a flop of a supplement, because it did not increase testosterone levels as first suspected, have at higher doses been discovered to be useful to facilitate recall of traumatic memories in the treatment of post traumatic stress disorder (PTSD). Also, Tabernanthe iboga and ibogaine have been used to treat PTSD and/or addiction to anabolic steroids.
Illicit use by groups
Anabolic steroid use has been associated with an antisocial lifestyle involving various types of criminality.
Steroid abuse among law enforcement is considered a problem by some. "It's a big problem, and from the number of cases, it's something we shouldn't ignore. It's not that we set out to target cops, but when we're in the middle of an active investigation into steroids, there have been quite a few cases that have led back to police officers," says Lawrence Payne, a spokesman for the United States Drug Enforcement Administration. The FBI Law Enforcement Bulletin stated that “Anabolic steroid abuse by police officers is a serious problem that merits greater awareness by departments across the country". It is also believed that police officers across the United Kingdom "are using criminals to buy steroids and abuse their power for sexual gratification" which he claims to be a top risk factor for police corruption.
Following the murder-suicide of Chris Benoit in 2007, the Oversight and Government Reform Committee investigated steroid usage in the wrestling industry. The Committee investigated WWE and Total Nonstop Action Wrestling (TNA), asking for documentation of their companies' drug policies. WWE CEO and Chairman, Linda and Vince McMahon respectively, both testified. The documents stated that 75 wrestlers—roughly 40 percent—had tested positive for drug use since 2006, most commonly for steroids.
Tragedies involving AAS abuse
Chris Benoit double-murder and suicide
Chris Benoit committed suicide after he killed his wife Nancy Benoit and strangled their seven-year-old son Daniel, led to numerous media accounts, and federal investigation into steroid abuse in professional wrestling.
On June 5, 2008, police discovered Jacobs, along with his "on-again, off-again" girlfriend, prominent fitness model Amanda Earhart-Savell, both dead of multiple gunshot wounds from a .40 caliber Glock handgun. Police shortly thereafter began characterizing their investigation as consistent with a murder-suicide. Police had been alerted to possible foul play after friends of Savell had reported she had been missing for several days, and officers were sent to check on their welfare at Jacobs' house located in Plano, Texas. Also found in Jacobs's house were "146 vials of steroids, 10 syringes, scales, bags with steroids and marijuana, a computer, and a .22 semi-automatic gun with ammunition."
Legal and sport restrictions
The legal status of anabolic steroids varies from country to country: some have stricter controls on their use or prescription than others though in many countries they are not illegal. In the U.S., anabolic steroids are currently listed as Schedule III controlled substances under the Controlled Substances Act, which makes simply possessing of such substances without a prescription, first offense, a federal crime punishable by up to one year in prison. Unlawful distribution or possession with intent to distribute anabolic steroids punishable as a first offense is punished by up to ten years in prison. In Canada, anabolic steroids and their derivatives are part of the Controlled drugs and substances act and are Schedule IV substances, meaning that it is illegal to obtain or sell them without a prescription; however, possession is not punishable, a consequence reserved for schedule I, II, or III substances. Those guilty of buying or selling anabolic steroids in Canada can be imprisoned for up to 18 months. Import and export also carry similar penalties. In Canada, researchers have concluded that steroid use among student athletes is extremely widespread. A study conducted in 1993 by the Canadian Centre for Drug-Free Sport found that nearly 83,000 Canadians between the ages of 11 and 18 use steroids. Anabolic steroids are also illegal without prescription in Australia, Argentina, Brazil and Portugal, and are listed as Class C Controlled Drugs in the United Kingdom. Anabolic steroids are readily available without a prescription in some countries such as Mexico and Thailand.
The history of the U.S. legislation on anabolic steroids goes back to the late 1980s, when the U.S. Congress considered placing anabolic steroids under the Controlled Substances Act following the controversy over Ben Johnson's victory at the 1988 Summer Olympics in Seoul. During deliberations, the American Medical Association (AMA), Drug Enforcement Administration (DEA), Food and Drug Administration (FDA) as well as the National Institute on Drug Abuse (NIDA) all opposed listing anabolic steroids as controlled substances, citing the fact that use of these hormones does not lead to the physical or psychological dependence required for such scheduling under the Controlled Substance Act. Nevertheless, anabolic steroids were added to Schedule III of the Controlled Substances Act in the Anabolic Steroids Control Act of 1990.
The same act also introduced more stringent controls with higher criminal penalties for offenses involving the illegal distribution of anabolic steroids and human growth hormone. By the early 1990s, after anabolic steroids were scheduled in the U.S., several pharmaceutical companies stopped manufacturing or marketing the products in the U.S., including Ciba, Searle, Syntex, and others. In the Controlled Substances Act, anabolic steroids are defined to be any drug or hormonal substance chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) that promote muscle growth. The act was amended by the Anabolic Steroid Control Act of 2004, which added prohormones to the list of controlled substances, with effect from January 20, 2005.
In the United Kingdom, anabolic steroids are classified as class C drugs for their illegal abuse potential, which puts them in the same class as benzodiazepines. Anabolic steroids are in Schedule 4, which is divided in 2 parts; Part 1 contains most of the benzodiazepines and Part 2 contains the anabolic and androgenic steroids.
Part 1 drugs are subject to full import and export controls with possession being an offence without an appropriate prescription. There is no restriction on the possession when it is part of a medicinal product. Part 2 drugs require a Home Office licence for importation and export unless the substance is in the form of a medicinal product and is for self-administration by a person.
Status in sports
Anabolic steroids are banned by all major sports bodies including Association of Tennis Professionals, Major League Baseball, Fédération Internationale de Football Association the Olympics, the National Basketball Association, the National Hockey League, and the National Football League. The World Anti-Doping Agency (WADA) maintains the list of performance-enhancing substances used by many major sports bodies and includes all anabolic agents, which includes all anabolic steroids and precursors as well as all hormones and related substances. Spain has passed an anti-doping law creating a national anti-doping agency. Italy passed a law in 2000 where penalties range up to three years in prison if an athlete has tested positive for banned substances. In 2006, Russian President Vladimir Putin signed into law ratification of the International Convention Against Doping in Sport which would encourage cooperation with WADA. Many other countries have similar legislation prohibiting anabolic steroids in sports including Denmark, France, the Netherlands and Sweden.
Detection of use
The most commonly employed human physiological specimen for detecting anabolic steroid usage is urine, although both blood and hair have been investigated for this purpose. The anabolic steroids, whether of endogenous or exogenous origin, are subject to extensive hepatic biotransformation by a variety of enzymatic pathways. The primary urinary metabolites may be detectable for up to 30 days after the last use, depending on the specific agent, dose and route of administration. A number of the drugs have common metabolic pathways, and their excretion profiles may overlap those of the endogenous steroids, making interpretation of testing results a very significant challenge to the analytical chemist. Methods for detection of the substances or their excretion products in urine specimens usually involve gas chromatography–mass spectrometry or liquid chromatography-mass spectrometry.
Anabolic steroids are frequently produced in pharmaceutical laboratories, but, in nations where stricter laws are present, they are also produced in small home-made underground laboratories, usually from raw substances imported from abroad. In these countries, the majority of steroids are obtained illegally through black market trade. These steroids are usually manufactured in other countries, and therefore must be smuggled across international borders. As with most significant smuggling operations, organized crime is involved.
In the late 2000s, the worldwide trade in illicit AAS increased significantly, and authorities announced record captures on three continents. In 2006, Finnish authorities announced a record seizure of 11.8 million AAS tablets. A year later, the DEA seized 11.4 million units of AAS in the largest U.S seizure ever. In the first three months of 2008, Australian customs reported a record 300 seizures of AAS shipments.
In the U.S., Canada, and Europe, illegal steroids are sometimes purchased just as any other illegal drug, through dealers who are able to obtain the drugs from a number of sources. Illegal anabolic steroids are sometimes sold at gyms and competitions, and through the mail, but may also be obtained through pharmacists, veterinarians, and physicians. In addition, a significant number of counterfeit products are sold as anabolic steroids, in particular via mail order from websites posing as overseas pharmacies. In the U.S., black-market importation continues from Mexico, Thailand, and other countries where steroids are more easily available, as they are legal.
Isolation of gonadal AAS
The use of gonadal steroids pre-dates their identification and isolation. Medical use of testicle extract began in the late 19th century while its effects on strength were still being studied. The isolation of gonadal steroids can be traced back to 1931, when Adolf Butenandt, a chemist in Marburg, purified 15 milligrams of the male hormone androstenone from tens of thousands of litres of urine. This steroid was subsequently synthesized in 1934 by Leopold Ruzicka, a chemist in Zurich.
In the 1930s, it was already known that the testes contain a more powerful androgen than androstenone, and three groups of scientists, funded by competing pharmaceutical companies in the Netherlands, Germany, and Switzerland, raced to isolate it. This hormone was first identified by Karoly Gyula David, E. Dingemanse, J. Freud and Ernst Laqueur in a May 1935 paper "On Crystalline Male Hormone from Testicles (Testosterone)." They named the hormone testosterone, from the stems of testicle and sterol, and the suffix of ketone. The chemical synthesis of testosterone was achieved in August that year, when Butenandt and G. Hanisch published a paper describing "A Method for Preparing Testosterone from Cholesterol." Only a week later, the third group, Ruzicka and A. Wettstein, announced a patent application in a paper "On the Artificial Preparation of the Testicular Hormone Testosterone (Androsten-3-one-17-ol)." Ruzicka and Butenandt were offered the 1939 Nobel Prize in Chemistry for their work, but the Nazi government forced Butenandt to decline the honor, although he accepted the prize after the end of World War II.
Clinical trials on humans, involving either oral doses of methyltestosterone or injections of testosterone propionate, began as early as 1937. Testosterone propionate is mentioned in a letter to the editor of Strength and Health magazine in 1938; this is the earliest known reference to an anabolic steroid in a U.S. weightlifting or bodybuilding magazine. There are often reported rumors that German soldiers were administered anabolic steroids during the Second World War, the aim being to increase their aggression and stamina, but these are, as yet, unproven. Adolf Hitler himself, according to his physician, was injected with testosterone derivatives to treat various ailments. AAS were used in experiments conducted by the Nazis on concentration camp inmates, and later by the allies attempting to treat the malnourished victims that survived Nazi camps. President John F. Kennedy was administered steroids both before and during his presidency.
Development of synthetic AAS
The development of muscle-building properties of testosterone was pursued in the 1940s, in the Soviet Union and in Eastern Bloc countries such as East Germany, where steroid programs were used to enhance the performance of Olympic and other amateur weight lifters. In response to the success of Russian weightlifters, the U.S. Olympic Team physician John Ziegler worked with synthetic chemists to develop an anabolic steroid with reduced androgenic effects. Ziegler's work resulted in the production of methandrostenolone, which Ciba Pharmaceuticals marketed as Dianabol. The new steroid was approved for use in the U.S. by the Food and Drug Administration (FDA) in 1958. It was most commonly administered to burn victims and the elderly. The drug's off-label users were mostly bodybuilders and weight lifters. Although Ziegler prescribed only small doses to athletes, he soon discovered that those having abused Dianabol suffered from enlarged prostates and atrophied testes. AAS were placed on the list of banned substances of the IOC in 1976, and a decade later the committee introduced 'out-of-competition' doping tests because many athletes used AAS in their training period rather than during competition.
Three major ideas governed modifications of testosterone into a multitude of AAS: Alkylation at 17-alpha position with methyl or ethyl group created orally active compounds because it slows the degradation of the drug by the liver; esterification of testosterone and nortestosterone at the 17-beta position allows the substance to be administered parenterally and increases the duration of effectiveness because agents soluble in oily liquids may be present in the body for several months; and alterations of the ring structure were applied for both oral and parenteral agents to seeking to obtain different anabolic to androgenic effect ratios.
- Androgen insensitivity syndrome
- Steroid rosacea
- Steroid use in Bollywood
- Bigger, Stronger, Faster*
- Juiced: Wild Times, Rampant 'Roids, Smash Hits & How Baseball Got Big
- Selective androgen receptor modulator
- Michael Powers, "Performance-Enhancing Drugs" in Joel Houglum, in Gary L. Harrelson, Deidre Leaver-Dunn, "Principles of Pharmacology for Athletic Trainers", SLACK Incorporated, 2005, ISBN 1-55642-594-5, p. 330
- Barrett-Connor E (1995). "Testosterone and risk factors for cardiovascular disease in men". Diabete Metab 21 (3): 156–61. PMID 7556805.
- Yamamoto Y, Moore R, Hess H, Guo G, Gonzalez F, Korach K, Maronpot R, Negishi M (2006). "Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity". J Biol Chem 281 (24): 16625–31. doi:10.1074/jbc.M602723200. PMID 16606610.
- De Piccoli B, Giada F, Benettin A, Sartori F, Piccolo E (1991). "Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function". Int J Sports Med 12 (4): 408–12. doi:10.1055/s-2007-1024703. PMID 1917226.
- Hartgens F, Kuipers H (2004). "Effects of androgenic-anabolic steroids in athletes". Sports Med 34 (8): 513–54. doi:10.2165/00007256-200434080-00003. PMID 15248788.
- Kicman AT, Gower DB (July 2003). "Anabolic steroids in sport: biochemical, clinical and analytical perspectives". Ann. Clin. Biochem. 40 (Pt 4): 321–56. doi:10.1258/000456303766476977. PMID 12880534.
- George P. Chrousos, The gonadal hormones and inhibitors, in Bertram G. Katzung (Ed.), Basic and Clinical Pharmacology, McGraw-Hill Professional, 2006, ISBN 0-07-145153-6, p. 674–676
- Cohen J, Collins R, Darkes J, Gwartney D (2007). "A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States". J Int Soc Sports Nutr 4: 12. doi:10.1186/1550-2783-4-12. PMC 2131752. PMID 17931410.
- Mutzebaugh C (1998). "Does the choice of alpha-AAS really make a difference?". HIV Hotline 8 (5–6): 10–1. PMID 11366379.
- Pereira de Jésus-Tran K, Côté PL, Cantin L, Blanchet J, Labrie F, Breton R (2006). "Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity". Protein Sci. 15 (5): 987–99. doi:10.1110/ps.051905906. PMC 2242507. PMID 16641486.
- Lavery DN, McEwan IJ (2005). "Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations". Biochem. J. 391 (Pt 3): 449–64. doi:10.1042/BJ20050872. PMC 1276946. PMID 16238547.
- Cheskis B (2004). "Regulation of cell signalling cascades by steroid hormones". J. Cell. Biochem. 93 (1): 20–7. doi:10.1002/jcb.20180. PMID 15352158.
- Roselli CE (1998). "The effect of anabolic-androgenic steroids on aromatase activity and androgen receptor binding in the rat preoptic area". Brain Res. 792 (2): 271–6. doi:10.1016/S0006-8993(98)00148-6. PMID 9593936.
- Brodsky I, Balagopal P, Nair K (1996). "Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study". J. Clin. Endocrinol. Metab. 81 (10): 3469–75. doi:10.1210/jc.81.10.3469. PMID 8855787.
- Hickson R, Czerwinski S, Falduto M, Young A (1990). "Glucocorticoid antagonism by exercise and androgenic-anabolic steroids". Med Sci Sports Exerc 22 (3): 331–40. doi:10.1249/00005768-199006000-00010. PMID 2199753.
- Singh R, Artaza J, Taylor W, Gonzalez-Cadavid N, Bhasin S (2003). "Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway". Endocrinology 144 (11): 5081–8. doi:10.1210/en.2003-0741. PMID 12960001.
- Schroeder E, Vallejo A, Zheng L, et al. (2005). "Six-week improvements in muscle mass and strength during androgen therapy in older men". J Gerontol a Biol Sci Med Sci 60 (12): 1586–92. doi:10.1093/gerona/60.12.1586. PMID 16424293.
- Grunfeld C, Kotler D, Dobs A, Glesby M, Bhasin S (2006). "Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study". J Acquir Immune Defic Syndr 41 (3): 304–14. doi:10.1097/01.qai.0000197546.56131.40. PMID 16540931.
- Giorgi A, Weatherby R, Murphy P (1999). "Muscular strength, body composition and health responses to the use of testosterone enanthate: a double blind study". Journal of science and medicine in sport / Sports Medicine Australia 2 (4): 341–55. doi:10.1016/S1440-2440(99)80007-3. PMID 10710012.
- Kuhn CM (2002). "Anabolic steroids". Recent Prog. Horm. Res. 57: 411–34. doi:10.1210/rp.57.1.411. PMID 12017555.
- "How Anabolic Steroids Alter Both Men And Women". Retrieved 2 January 2014.
- L.G. Hershberger, E.G. Shipley, R.K. Meyer, Myotropic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method, Proc. Soc. Exp. Biol. Med. 83 (1953), 175–180
- Hervey GR, Hutchinson I, Knibbs AV, Burkinshaw L, Jones PR, Norgan NG, Levell MJ (October 1976). ""Anabolic" effects of methandienone in men undergoing athletic training". Lancet 2 (7988): 699–702. doi:10.1016/S0140-6736(76)90001-5. PMID 61389.
- HHervey GR, Knibbs AV, Burkinshaw L, Morgan DB, Jones PR, Chettle DR, Vartsky D (April 1981). "Effects of methandienone on the performance and body composition of men undergoing athletic training". Clin. Sci. 60 (4): 457–61. PMID 7018798.
- Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R (July 1996). "The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men". N. Engl. J. Med. 335 (1): 1–7. doi:10.1056/NEJM199607043350101. PMID 8637535.
- Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW (December 2001). "Testosterone dose-response relationships in healthy young men". Am. J. Physiol. Endocrinol. Metab. 281 (6): E1172–81. PMID 11701431.
- Basaria S, Wahlstrom JT, Dobs AS (November 2001). "Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases". J. Clin. Endocrinol. Metab. 86 (11): 5108–17. doi:10.1210/jcem.86.11.7983. PMID 11701661.
- Ranke MB, Bierich JR (1986). "Treatment of growth hormone deficiency". Clinics in endocrinology and metabolism 15 (3): 495–510. doi:10.1016/S0300-595X(86)80008-1. PMID 2429792.
- Grunfeld C, Kotler D, Dobs A, Glesby M, Bhasin S (2006). "Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study". J. Acquir. Immune Defic. Syndr. 41 (3): 304–14. doi:10.1097/01.qai.0000197546.56131.40. PMID 16540931.
- Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R (1996). "Oxandrolone in AIDS-wasting myopathy". AIDS 10 (14): 1657–62. doi:10.1097/00002030-199612000-00010. PMID 8970686.
- Arslanian S, Suprasongsin C (1997). "Testosterone treatment in adolescents with delayed puberty: changes in body composition, protein, fat, and glucose metabolism". J. Clin. Endocrinol. Metab. 82 (10): 3213–20. doi:10.1210/jc.82.10.3213. PMID 9329341.
- Matsumoto A (1990). "Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production". J. Clin. Endocrinol. Metab. 70 (1): 282–7. doi:10.1210/jcem-70-1-282. PMID 2104626.
- Aribarg A, Sukcharoen N, Chanprasit Y, Ngeamvijawat J, Kriangsinyos R (1996). "Suppression of spermatogenesis by testosterone enanthate in Thai men". Journal of the Medical Association of Thailand = Chotmaihet thangphaet 79 (10): 624–9. PMID 8996996.
- Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG (2001). "Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels". J. Gerontol. A Biol. Sci. Med. Sci. 56 (5): M266–72. doi:10.1093/gerona/56.5.M266. PMID 11320105.
- Baum NH, Crespi CA (2007). "Testosterone replacement in elderly men". Geriatrics 62 (9): 14–8. PMID 17824721.
- Francis RM (2001). "Androgen replacement in aging men". Calcif. Tissue Int. 69 (4): 235–8. doi:10.1007/s00223-001-1051-9. PMID 11730258.
- Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ, Smith GE, Khosla S, Jensen MD (October 2006). "DHEA in elderly women and DHEA or testosterone in elderly men". N. Engl. J. Med. 355 (16): 1647–59. doi:10.1056/NEJMoa054629. PMID 17050889.
- Shah K, Montoya C, Persons RK (April 2007). "Clinical inquiries. Do testosterone injections increase libido for elderly hypogonadal patients?". J Fam Pract 56 (4): 301–3. PMID 17403329.
- Yassin AA, Saad F (March 2007). "Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only". J Sex Med 4 (2): 497–501. doi:10.1111/j.1743-6109.2007.00442.x. PMID 17367445.
- Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA (December 1997). "Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men". Clin. Endocrinol. (Oxf) 47 (6): 727–37. doi:10.1046/j.1365-2265.1997.3071113.x. PMID 9497881.
- Nieschlag E, Büchter D, Von Eckardstein S, Abshagen K, Simoni M, Behre HM (December 1999). "Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men". Clin. Endocrinol. (Oxf) 51 (6): 757–63. doi:10.1046/j.1365-2265.1999.00881.x. PMID 10619981.
- Moore E, Wisniewski A, Dobs A (August 2003). "Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects". J. Clin. Endocrinol. Metab. 88 (8): 3467–73. doi:10.1210/jc.2002-021967. PMID 12915619.
- "Most steroid users are not athletes: study". Reuters. 2007-11-21. Retrieved 2014-01-03.
- Sjöqvist F, Garle M, Rane A (May 2008). "Use of doping agents, in particular anabolic steroids, in sports and society". Lancet 371 (9627): 1872–82. doi:10.1016/S0140-6736(08)60801-6. PMID 18514731.
- Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS (1993). "Anabolic-androgenic steroid use in the United States". JAMA 270 (10): 1217–21. doi:10.1001/jama.270.10.1217. PMID 8355384."
- McCabe SE, Brower KJ, West BT, Nelson TF, Wechsler H (2007). "Trends in non-medical use of anabolic steroids by U.S. college students: Results from four national surveys". Drug and alcohol dependence 90 (2–3): 243–51. doi:10.1016/j.drugalcdep.2007.04.004. PMC 2383927. PMID 17512138.
- Parkinson AB, Evans NA (April 2006). "Anabolic androgenic steroids: a survey of 500 users". Med Sci Sports Exerc 38 (4): 644–51. doi:10.1249/01.mss.0000210194.56834.5d. PMID 16679978.
- Copeland J, Peters R, Dillon P (March 1998). "A study of 100 anabolic-androgenic steroid users". Med. J. Aust. 168 (6): 311–2. PMID 9549549.
- Eastley, Tony (January 18, 2006). "Steroid study debunks user stereotypes". ABC. Retrieved 2014-01-03.
- Pope HG, Kanayama G, Ionescu-Pioggia M, Hudson JI (September 2004). "Anabolic steroid users' attitudes towards physicians". Addiction 99 (9): 1189–94. doi:10.1111/j.1360-0443.2004.00781.x. PMID 15317640.
- Kanayama G, Barry S, Hudson JI, Pope HG (April 2006). "Body image and attitudes toward male roles in anabolic-androgenic steroid users". Am J Psychiatry 163 (4): 697–703. doi:10.1176/appi.ajp.163.4.697. PMID 16585446.
- Hickson R, Czerwinski S, Falduto M, Young A (1990). "Glucocorticoid antagonism by exercise and androgenic-anabolic steroids". Medicine and science in sports and exercise 22 (3): 331–40. doi:10.1249/00005768-199006000-00010. PMID 2199753.
- Trenton AJ, Currier GW (2005). "Behavioural manifestations of anabolic steroid use". CNS Drugs 19 (7): 571–95. doi:10.2165/00023210-200519070-00002. PMID 15984895.
- Kanayama G, Hudson JI, Pope HG (November 2008). "Long-Term Psychiatric and Medical Consequences of Anabolic-Androgenic Steroid Abuse: A Looming Public Health Concern?". Drug Alcohol Depend 98 (1–2): 1–12. doi:10.1016/j.drugalcdep.2008.05.004. PMC 2646607. PMID 18599224.
- Brower KJ (October 2002). "Anabolic steroid abuse and dependence". Curr Psychiatry Rep 4 (5): 377–87. doi:10.1007/s11920-002-0086-6. PMID 12230967.
- Fudala P, Weinrieb R, Calarco J, Kampman K, Boardman C (2003). "An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: seven case studies". Annals of Clinical Psychiatry 15 (2): 121–30. doi:10.3109/10401230309085677. PMID 12938869.
- Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS (2006). "Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse". Eur. Psychiatry 21 (8): 551–62. doi:10.1016/j.eurpsy.2005.09.001. PMID 16356691.
- Rashid H, Ormerod S, Day E (2007). "Anabolic androgenic steroids: What the psychiatrist needs to know". Advances in Psychiatric Treatment 13 (3): 203. doi:10.1192/apt.bp.105.000935.
- Cooper CJ, Noakes TD, Dunne T, Lambert MI, Rochford K (September 1996). "A high prevalence of abnormal personality traits in chronic users of anabolic-androgenic steroids". Br J Sports Med 30 (3): 246–50. doi:10.1136/bjsm.30.3.246. PMC 1332342. PMID 8889121.
- "Dr. Ritchi Morris". Vitalquests.org. Retrieved 2013-12-01.
- Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG (December 2009). "Anabolic-androgenic steroid dependence: an emerging disorder". Addiction 104 (12): 1966–78. doi:10.1111/j.1360-0443.2009.02734.x. PMC 2780436. PMID 19922565.
- Eisenberg ER, Galloway GP. "Anabolic androgenic steroids". In Lowinson JH, Ruiz P, Millman RB. Substance Abuse: A Comprehensive Textbook. Lippincott Williams & Wilkins. ASIN B0049VACMW.
- Lindström M, Nilsson AL, Katzman PL, Janzon L, Dymling JF (1990). "Use of anabolic-androgenic steroids among body builders--frequency and attitudes". J. Intern. Med. 227 (6): 407–11. doi:10.1111/j.1365-2796.1990.tb00179.x. PMID 2351927.
- Pat Lenehan, "Anabolic Steroids: And Other Performance-enhancing Drugs", CRC Press, 2003, ISBN 0-415-28030-3, page 23
- Thiblin I, Petersson A (February 2005). "Pharmacoepidemiology of anabolic androgenic steroids: a review". Fundam Clin Pharmacol 19 (1): 27–44. doi:10.1111/j.1472-8206.2004.00298.x. PMID 15660958.
- Beaver KM, Vaughn MG, Delisi M, Wright JP (December 2008). "Anabolic-Androgenic Steroid Use and Involvement in Violent Behavior in a Nationally Representative Sample of Young Adult Males in the United States". Am J Public Health 98 (12): 2185–7. doi:10.2105/AJPH.2008.137018. PMC 2636528. PMID 18923108.
- Bahrke MS, Yesalis CE, Wright JE (1996). "Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update". Sports medicine (Auckland, N.Z.) 22 (6): 367–90. doi:10.2165/00007256-199622060-00005. PMID 8969015.
- Tricker R, Casaburi R, Storer TW, Clevenger B, Berman N, Shirazi A, Bhasin S (October 1996). "The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men--a clinical research center study". J. Clin. Endocrinol. Metab. 81 (10): 3754–8. doi:10.1210/jcem.81.10.8855834. PMID 8855834.
- Pope HG, Kouri EM, Hudson JI (February 2000). "Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial". Arch. Gen. Psychiatry 57 (2): 133–40; discussion 155–6. doi:10.1001/archpsyc.57.2.133. PMID 10665615.
- Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS, Toli PN (2006). "Psychiatric and hostility factors related to use of anabolic steroids in monozygotic twins". Eur. Psychiatry 21 (8): 563–9. doi:10.1016/j.eurpsy.2005.11.002. PMID 16529916.
- Perry PJ, Kutscher EC, Lund BC, Yates WR, Holman TL, Demers L (May 2003). "Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use". J. Forensic Sci. 48 (3): 646–51. PMID 12762541.
- "Teens & Steroids: A Dangerous Mix". CBS (CBS Broadcasting Inc.). 2004-06-03. Archived from the original on 10 July 2007. Retrieved 2007-06-27.
- Uzych L (February 1992). "Anabolic-androgenic steroids and psychiatric-related effects: a review". Can J Psychiatry 37 (1): 23–8. PMID 1551042.
- "Anabolic Steroids and Suicide - A Brief Review of the Evidence". Thinksteroids.com. 2005-07-12. Retrieved 2013-12-01.
- Grace F, Sculthorpe N, Baker J, Davies B (2003). "Blood pressure and rate pressure product response in males using high-dose anabolic-androgenic steroids (AAS)". J Sci Med Sport 6 (3): 307–12. doi:10.1016/S1440-2440(03)80024-5. PMID 14609147.
- "DailyMed: About DailyMed". Dailymed.nlm.nih.gov. Retrieved 2008-11-03.
- Bagatell C, Knopp R, Vale W, Rivier J, Bremner W (1992). "Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels". Annals of Internal Medicine 116 (12 Pt 1): 967–73. doi:10.7326/0003-4819-116-12-967. PMID 1586105.
- Mewis C, Spyridopoulos I, Kühlkamp V, Seipel L (1996). "Manifestation of severe coronary heart disease after anabolic drug abuse". Clinical Cardiology 19 (2): 153–5. doi:10.1002/clc.4960190216. PMID 8821428.
- Melnik B, Jansen T, Grabbe S (2007). "Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem". Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 5 (2): 110–7. doi:10.1111/j.1610-0387.2007.06176.x. PMID 17274777.
- Vierhapper H, Maier H, Nowotny P, Waldhäusl W (July 2003). "Production rates of testosterone and of dihydrotestosterone in female pattern hair loss". Metab. Clin. Exp. 52 (7): 927–9. doi:10.1016/S0026-0495(03)00060-X. PMID 12870172.
- Irving L, Wall M, Neumark-Sztainer D, Story M (2002). "Steroid use among adolescents: findings from Project EAT". The Journal of Adolescent Health 30 (4): 243–52. doi:10.1016/S1054-139X(01)00414-1. PMID 11927236.
- "Known and Probable Human Carcinogens". American Cancer Society. 2011-06-29.
- Sullivan ML, Martinez CM, Gallagher EJ (1999). "Atrial fibrillation and anabolic steroids". The Journal of emergency medicine 17 (5): 851–7. doi:10.1016/S0736-4679(99)00095-5. PMID 10499702.
- Dickerman RD, Schaller F, McConathy WJ (1998). "Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid Use". Cardiology 90 (2): 145–8. doi:10.1159/000006834. PMID 9778553.
- George KP, Wolfe LA, Burggraf GW (1991). "The 'athletic heart syndrome'. A critical review". Sports medicine (Auckland, N.Z.) 11 (5): 300–30. doi:10.2165/00007256-199111050-00003. PMID 1829849.
- Dickerman R, Schaller F, Zachariah N, McConathy W (1997). "Left ventricular size and function in elite bodybuilders using anabolic steroids". Clin J Sport Med 7 (2): 90–3. doi:10.1097/00042752-199704000-00003. PMID 9113423.
- Salke RC, Rowland TW, Burke EJ (1985). "Left ventricular size and function in body builders using anabolic steroids". Medicine and science in sports and exercise 17 (6): 701–4. doi:10.1249/00005768-198512000-00014. PMID 4079743.
- Tokar, Steve (February 2006). "Liver Damage And Increased Heart Attack Risk Caused By Anabolic Steroid Use". University of California – San Francisco. Retrieved 2007-04-24.
- "Fact Sheet: Side Effects of Steroid Use - ABC News". Abcnews.go.com. 2005-03-17. Retrieved 2013-12-01.
- Marcus R, Korenman S (1976). "Estrogens and the human male". Annu Rev Med 27: 357–70. doi:10.1146/annurev.me.27.020176.002041. PMID 779604.
- Hoffman JR, Ratamess NA (June 1, 2006). "Medical Issues Associated with Anabolic Steroid Use: Are they Exaggerated?" (PDF). Journal of Sports Science and Medicine. Archived from the original on 20 June 2007. Retrieved 2007-05-08.
- Meriggiola M, Costantino A, Bremner W, Morselli-Labate A (2002). "Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen". J. Androl. 23 (5): 684–90. PMID 12185103.
- Alén M, Reinilä M, Vihko R (1985). "Response of serum hormones to androgen administration in power athletes". Medicine and science in sports and exercise 17 (3): 354–9. doi:10.1249/00005768-198506000-00009. PMID 2991700.
- Manikkam M, Crespi EJ, Doop DD, Herkimer C, Lee JS, Yu S, Brown MB, Foster DL, Padmanabhan V (February 2004). "Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep". Endocrinology 145 (2): 790–8. doi:10.1210/en.2003-0478. PMID 14576190.
- Herlitz, Leal C.; Markowitz, Glen S.; Farris, Alton B.; Schwimmer, Joshua A.; Stokes, Michael B.; Kunis, Cheryl; Colvin, Robert B.; D'Agati, Vivette D. (October 29, 2009). "Bodybuilding With Steroids Damages Kidneys". 42nd Annual Meeting and Scientific Exposition of the American Society of Nephrology. Lay summary – ScienceDaily (October 30, 2009).
- Dopinglinkki > Anabolic steroids induce long-term changes in the brain
- Wood RI (November 2004). "Reinforcing aspects of androgens". Physiol. Behav. 83 (2): 279–89. doi:10.1016/j.physbeh.2004.08.012. PMID 15488545.
- Abuse of steroids is rivalling heroin use in Britain - Mirror Online
- Midgley SJ, Heather N, Davies JB (1999). "Dependence-Producing Potential of Anabolic-Androgenic Steroids". Addiction Research & Theory 7 (6): 539. doi:10.3109/16066359909004404.
- "The price of steroids | Men's Fitness UK". Mensfitness.co.uk. 2008-09-03. Retrieved 2013-12-01.
- Scally MC, Tan RS (October 2009). "Complexities in clarifying the diagnostic criteria for anabolic-androgenic steroid dependence". Am J Psychiatry 166 (10): 1187; author reply 1188. doi:10.1176/appi.ajp.2009.09060846. PMID 19797448.
- "2014 ICD-10-CM Diagnosis Code F55.3 : Abuse of steroids or hormones". Icd10data.com. Retrieved 2013-12-01.
- "DrugFacts: Anabolic Steroids | National Institute on Drug Abuse". Drugabuse.gov. Retrieved 2013-12-01.
- Skarberg K, Engstrom I (2007). "Troubled social background of male anabolic-androgenic steroid abusers in treatment". Subst Abuse Treat Prev Policy 2: 20. doi:10.1186/1747-597X-2-20. PMC 1995193. PMID 17615062.
- "Why do people abuse anabolic steroids? | National Institute on Drug Abuse". Drugabuse.gov. Retrieved 2013-12-01.
- van der Kolk, Bessel A. (1995). "The Treatment of Post Traumatic Stress Disorder". In Hobfoll, Stevan E.; De Vries, Marten W. Extreme stress and communities: impact and intervention. Boston: Kluwer Academic Publishers. pp. 421–44. ISBN 978-0-7923-3468-2.
- Klötz F, Garle M, Granath F, Thiblin I (November 2006). "Criminality among individuals testing positive for the presence of anabolic androgenic steroids". Arch. Gen. Psychiatry 63 (11): 1274–9. doi:10.1001/archpsyc.63.11.1274. PMID 17088508.
- Keeping, Juliana (27 December 2010). "Steroid abuse among law enforcement a problem nationwide". The Ann Arbor News. Retrieved 1 December 2013.
- "Anabolic Steroid Use and Abuse by Police Officers: Policy & Prevention". The Police Chief. June 2008. Retrieved 1 December 2013.
- "Chief constable admits police officers across UK 'are using criminals to buy steroids and abuse their power for sexual gratification'". Daily Mail. 22 January 2013. Retrieved 1 December 2013.
- Brian Lockhart (2010-03-01). "WWE steroid investigation: A controversy McMahon 'doesn't need'". Greenwich Time. Retrieved 2010-03-01.
- documents[dead link]
- "Deposition details McMahon steroid testimony | News from southeastern Connecticut". The Day. 2007-12-13. Retrieved 2010-08-14.
- Assael, Shaun. "Former steroid dealer wanted to make a difference", ESPN, the Magazine, June 5, 2008. Accessed June 23, 2008.
- Ball, Linda Stewart. "Police say steroid dealer killed himself", Associated Press, Jun 6, 2008. Accessed June 23, 2008.[dead link]
- "Steroid Dealer Is Found Shot To Death", The Washington Post, Friday, June 6, 2008; Page E02
- "Earhart-Savell death ruled murder[dead link]", WFAA, June 9, 2008.
- "Title 21 United States Code (USC) Controlled Substances Act". US Department of Justice. Archived from the original on 1 August 2009. Retrieved 2009-09-07.
- Controlled Drugs and Substances Act, S.C. 1996, c. 19, s. 4(7) (Controlled Drugs and Substances Act at Department of Justice)
- Deacon, James (2 May 1994). "Biceps in a bottle". Maclean's: 52.
- "Steroids". Australian Institute of Criminology. 2006. Archived from the original on 2007-04-05. Retrieved 2007-05-06.
- "Library of congress search". Library of congress. Retrieved 2007-05-06.[dead link]
- H.R. 4658
- "News from DEA, Congressional Testimony, 03/16/04". Retrieved 2007-04-24.[dead link]
- "Patient.co.uk Controlled Drugs". Egton Medical Information Systems Limited. Retrieved 8 August 2013.
- "FIFA Anit-Doping Regulations". Es.fifa.com. Retrieved 2013-12-01.
- "Olympic movement anti-doping code" (PDF). International Olympic Committee. 1999. Retrieved 2007-05-06.
- "The nba and nbpa anti-drug program". NBA Policy. findlaw.com. 1999. Retrieved 2007-05-06.
- "NHL/NHLPA performance-enhancing substances program summary". nhlpa.com. Archived from the original on 2 June 2007. Retrieved 2007-05-06.
- "List of Prohibited Substances" (PDF). nflpa.com. 2006. Retrieved 2007-05-06.[dead link]
- "World anti-doping code" (PDF). WADA. 2003. Archived from the original on 7 August 2007. Retrieved 2007-07-10.
- "Prohibited list of 2005" (PDF). WADA. 2005. Retrieved 2007-05-06.
- "Spain's senate passes anti-doping law". Herald Tribune. Associated Press. October 5, 2006. Retrieved 2007-05-06.[dead link]
- Johnson, Kevin (2006-02-20). "Italian anti-doping laws could mean 3 years in jail". USA Today. Retrieved 2007-05-06.
- "Act on promotion of doping-free sport" (PDF). kum.dk. 2004. Retrieved 2007-05-06.[dead link]
- "Protection of health of athletes and the fight against doping" (PDF). WADA. 2006. Retrieved 2007-05-06.
- "Anti-doping legislation in the netherlands" (PDF). WADA. 2006. Retrieved 2007-05-06.
- "The Swedish Act prohibiting certain doping substances (1991:1969)" (PDF). WADA. 1991. Retrieved 2007-05-06.
- Mareck U, Geyer H, Opfermann G, Thevis M, Schänzer W (July 2008). "Factors influencing the steroid profile in doping control analysis". J Mass Spectrom 43 (7): 877–91. doi:10.1002/jms.1457. PMID 18570179.
- Fragkaki AG, Angelis YS, Tsantili-Kakoulidou A, Koupparis M, Georgakopoulos C (May 2009). "Schemes of metabolic patterns of anabolic androgenic steroids for the estimation of metabolites of designer steroids in human urine". J. Steroid Biochem. Mol. Biol. 115 (1–2): 44–61. doi:10.1016/j.jsbmb.2009.02.016. PMID 19429460.
- Blackledge RD (August 2009). "Bad science: the instrumental data in the Floyd Landis case". Clin. Chim. Acta 406 (1–2): 8–13. doi:10.1016/j.cca.2009.05.016. PMID 19465014.
- Baselt, Randall Clint (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 95, 393, 403, 649, 695, 952, 962, 1078, 1156, 1170, 1442, 1501, 1581. ISBN 978-0-9626523-7-0.
- Assael, Shaun (2007-09-24). "'Raw Deal' busts labs across U.S., many supplied by China". ESPN The Magazine. Archived from the original on 14 October 2007. Retrieved 2007-09-24.
- Yesalis, C (2000). "Source of Anabolic Steroids". Anabolic Steroids in Sport and Exercise. Champaign, Ill.: Human Kinetics. ISBN 978-0-88011-786-9.
- Black, Terry (1996). "Does the Ban on Drugs in Sport Improve Societal Welfare?". Faculty of Business, Queensland University of Technology. Retrieved 2007-04-24.
- Richard W. Pound. (2006). "Organized Crime". Inside dope : how drugs are the biggest threat to sports, why you should care, and what can be done about them. Mississaug, Ontario: Wiley. p. 175. ISBN 978-0-470-83733-7.
- Kanayama G, Hudson JI, Pope HG (November 2008). "Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?". Drug Alcohol Depend 98 (1–2): 1–12. doi:10.1016/j.drugalcdep.2008.05.004. PMC 2646607. PMID 18599224.
- "Steroids". National Institute on Drug Abuse. GDCADA. Archived from the original on 2007-09-11. Retrieved 2007-09-13.
- "The Drug Enforcement Administration's International Operations (Redacted)". Office of the Inspector General. USDOJ. February 2007. Retrieved 2014-01-02.
- Hoberman JM, Yesalis CE (1995). "The history of synthetic testosterone". Scientific American 272 (2): 76–81. doi:10.1038/scientificamerican0295-76. PMID 7817189.
- Freeman ER, Bloom DA, McGuire EJ (2001). "A brief history of testosterone". Journal of Urology 165 (2): 371–373. doi:10.1097/00005392-200102000-00004. PMID 11176375.
- David K, Dingemanse E, Freud J, Laqueur L (1935). "Uber krystallinisches mannliches Hormon aus Hoden (Testosteron) wirksamer als aus harn oder aus Cholesterin bereitetes Androsteron". Hoppe Seylers Z Physiol Chem 233 (5–6): 281. doi:10.1515/bchm2.1935.233.5-6.281.
- Butenandt A, Hanisch G (1935). "Über die Umwandlung des Dehydro-androsterons in Δ4-Androsten-ol-(17)-0n-(3) (Testosteron); ein Weg zur Darstellung des Testosterons aus Cholesterin (Vorläuf. Mitteil.)" [On the conversion of dehydro-Δ4-androstene androsterons in-ol (17) 0n (3) (testosterone), a way to represent the testosterone from cholesterol (Vorläuf. msgs.)]. Berichte der deutschen chemischen Gesellschaft (A and B Series) (in German) 68 (9): 1859–62. doi:10.1002/cber.19350680937.
- Ruzicka L, Wettstein A (1935). "Sexualhormone VII. Uber die kunstliche Herstellung des Testikelhormons. Testosteron (Androsten-3-one-17-ol.)" [Sex hormones VII About the artificial production of testosterone Testikelhormons (androstene-3-one-17-ol)]. Helvetica Chimica Acta (in German) 18: 1264–75. doi:10.1002/hlca.193501801176.
- Pat Lenehan, "Anabolic Steroids: And Other Performance-enhancing Drugs", CRC Press, 2003, ISBN 0-415-28030-3, page 6
- Taylor WN (January 1, 2009). Anabolic Steroids and the Athlete. McFarland & Company. p. 181. ISBN 0-7864-1128-7.
- Senior Correspondent Ray Suarez and physician Jeffrey Kelman (2002-11-18). "President Kennedy's Health Secrets". PBS NewsHour. Public Broadcasting System.
- Calfee R, Fadale P (2006). "Popular ergogenic drugs and supplements in young athletes". Pediatrics 117 (3): e577–89. doi:10.1542/peds.2005-1429. PMID 16510635.
- Justin Peters The Man Behind the Juice, Slate Friday, Feb. 18, 2005, Accessed 29 April 2008
- Yesalis CE (2000). Anabolic Steroids in Sport and Exercise. Human Kinetics. ISBN 0-88011-786-9.
- Daniels RC (February 1, 2003). The Anabolic Steroid Handbook. RCD Books. p. 80. ISBN 0-9548227-0-6.
- Gallaway S (January 15, 1997). The Steroid Bible (3rd Sprl ed.). Belle Intl. p. 125. ISBN 1-890342-00-9.
- Llewellyn W (January 28, 2007). ANABOLICS 2007 : Anabolic Steroid Reference Manual (6th ed.). Body of Science. p. 988. ISBN 978-0-9679304-6-6.
- Roberts A, Clapp B (January 2006). Anabolic Steroids: Ultimate Research Guide. Anabolic Books, LLC. p. 394. ISBN 1-59975-100-3.
- Tygart TT (December 2009). "Steroids, the Media, and Youth". Prevention Researcher Integrated Research Services, Inc., (SIRS Researcher) 16 (7–9).
- Eisenhauer L (Nov 7, 2005). "Do I Look OK?". St. Louis Post-Dispatch (St. Louis, MO). Retrieved 25 Oct 2010.
- Dmoz Directory of websites on anabolic steroids
- National Institute on Drug Abuse: "NIDA for Teens: Anabolic Steroids".